Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): Protocol for a randomised controlled trial

Trials

Volumn 18, Issue 1, 2017, Pages

  Chalmers, Joanne R ^a   Haines, Rachel H ^a   Mitchell, Eleanor J ^a   Thomas, Kim S ^a   Brown, Sara J ^b,c   Ridd, Matthew ^d   Lawton, Sandra ^e   Simpson, Eric L ^f   Cork, Michael J ^g   Sach, Tracey H ^h   Bradshaw, Lucy E ^a   Montgomery, Alan A ^a   Boyle, Robert J ⁱ   Williams, Hywel C ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e Rotherham NHS Foundation Trust   (United Kingdom)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g Department of Infection and Immunity ^*  (United Kingdom)

^h UNIVERSITY OF EAST ANGLIA   (United Kingdom)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Atopic dermatitis; Barrier enhancement; Core outcomes; Eczema; Emollient; Filaggrin; Prevention; Protocol; Randomised controlled trial

Indexed keywords

EMOLLIENT AGENT; DIPROBASE; DOUBLEBASE; ORGANIC COMPOUND;

ALLERGIC RHINITIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ECZEMA AREA AND SEVERITY INDEX; EGG ALLERGY; ENGLAND; FIRST-DEGREE RELATIVE; FOLLOW UP; FOOD ALLERGY; GENOTYPE; HEALTH CARE UTILIZATION; HIGH RISK INFANT; HUMAN; INFANT; MILK ALLERGY; MULTICENTER STUDY; ONSET AGE; OUTCOME ASSESSMENT; PATIENT ORIENTED ECZEMA MEASURE; PEANUT ALLERGY; POLLEN ALLERGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSITIZATION; SKIN CARE; UK WORKING PARTY DIAGNOSTIC CRITERIA FOR ATOPIC ECZEMA; WHEEZING; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMUNITY CARE; COST BENEFIT ANALYSIS; CUTANEOUS DRUG ADMINISTRATION; DRUG COST; ECONOMICS; FEMALE; GENETICS; MALE; METHODOLOGY; NEWBORN; PRESCHOOL CHILD; QUESTIONNAIRE; SECONDARY HEALTH CARE; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; CHILD, PRESCHOOL; CLINICAL PROTOCOLS; COMMUNITY HEALTH SERVICES; COST-BENEFIT ANALYSIS; DERMATITIS, ATOPIC; DRUG COSTS; EMOLLIENTS; ENGLAND; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; ORGANIC CHEMICALS; RESEARCH DESIGN; SECONDARY CARE; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 85025064479     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-017-2031-3     Document Type: Article

References (44)

1. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832-6.
2. Malik G, Tagiyeva N, Aucott L, McNeill G, Turner SW. Changing trends in asthma in 9-12 year olds between 1964 and 2009. Arch Dis Child. 2011;96(3):227-31.
3. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124(6):1251-8. e23.
4. Williams HC, Wüthrich B. Atopic dermatitis; The epidemiology, causes and prevention of atopic eczema. Cambridge University Press; 2000
5. Kemp AS. Cost of illness of atopic dermatitis in children: a societal perspective. Pharmacoeconomics. 2003;21(2):105-13.
6. Martin PE, Eckert JK, Koplin JJ, Lowe AJ, Gurrin LC, Dharmage SC, et al. Which infants with eczema are at risk of food allergy? Results from a population-based cohort. Clin Exp Allergy. 2015;45(1):255-64.
7. van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol. 2007;120(3):565-9.
8. von Kobyletzki LB, Bornehag CG, Hasselgren M, Larsson M, Lindstrom CB, Svensson A. Eczema in early childhood is strongly associated with the development of asthma and rhinitis in a prospective cohort. BMC Dermatol. 2012;12:11.
9. Punekar YS, Sheikh A. Establishing the sequential progression of multiple allergic diagnoses in a UK birth cohort using the General Practice Research Database. Clin Exp Allergy. 2009;39(12):1889-95.
10. Zheng T, Yu J, Oh MH, Zhu Z. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy, Asthma Immunol Res. 2011;3(2):67-73.
11. Gupta R, Sheikh A, Strachan DP, Anderson HR. Burden of allergic disease in the UK: secondary analyses of national databases. Clin Exp Allergy. 2004;34(4):520-6.
12. Tsakok T, Marrs T, Mohsin M, Baron S, du Toit G, Till S, et al. Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol. 2016;137(4):1071-8.
13. Brough HA, Liu AH, Sicherer S, Makinson K, Douiri A, Brown SJ, et al. Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. J Allergy Clin Immunol. 2015;135(1):164-70.
14. Fallon PG, Sasaki T, Sandilands A, Campbell LE, Saunders SP, Mangan NE, et al. A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. Nat Genet. 2009;41(5):602-8.
15. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315-27.
16. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441-6.
17. Williams C, Wilkinson SM, McShane P, Lewis J, Pennington D, Pierce S, et al. A double-blind, randomized study to assess the effectiveness of different moisturizers in preventing dermatitis induced by hand washing to simulate healthcare use. Br J Dermatol. 2010;162(5):1088-92.
18. Edwards WH, Conner JM, Soll RF. The effect of prophylactic ointment therapy on nosocomial sepsis rates and skin integrity in infants with birth weights of 501 to 1000g. Pediatrics. 2004;113(5):1195-203.
19. Wiren K, Nohlgard C, Nyberg F, Holm L, Svensson M, Johannesson A, et al. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol. 2009;23(11):1267-72.
20. Danby SG, Chalmers J, Brown K, Williams HC, Cork MJ. A functional mechanistic study of the effect of emollients on the structure and function of the skin barrier. Br J Dermatol. 2016;175(5):1011-9.
21. Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818-23.
22. Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):824-30. e6.
23. Centre of Evidence Based Dermatology. The BEEP Trial Available from: www.beepstudy.org. Accessed on 17 Mar 2017.
24. NICE. Postnatal care up to 8weeks after birth. Available from: https://www.nice.org.uk/guidance/cg37. Accessed on 17 Mar 2017.
25. Danby SG, Al-Enezi T, Sultan A, Chittock J, Kennedy K, Cork MJ. The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis. Br J Dermatol. 2011;165(2):329-34.
26. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol. 1994;131(3):406-16.
27. Schmitt J, Spuls PI, Thomas KS, Simpson E, Furue M, Deckert S, et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134(4):800-7.
28. Spuls PI, Gerbens LA, Simpson E, Apfelbacher CJ, Chalmers JR, Thomas KS, et al. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. Br J Dermatol. 2016.
29. Gerbens LA, Prinsen CA, Chalmers JR, Drucker AM, von Kobyletzki LB, Limpens J, et al. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review. Allergy. 2016.
30. Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol. 2013;132(6):1337-47.
31. Sandilands A, Terron-Kwiatkowski A, Hull PR, O'Regan GM, Clayton TH, Watson RM, et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet. 2007;39(5):650-4.
32. British Society for Allergy & Clinical Immunology (BSACI). Paediatric Skin Prick Testing. Available from: http://www.bsaci.org/_literature_121183/Paediatric_skin_prick_testing_guideline. Accessed on 17 Mar 2017.
33. Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW, et al. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy Clin Immunol. 2012;130(6):1260-74.
34. Grabenhenrich LB, Reich A, Bellach J, Trendelenburg V, Sprikkelman AB, Roberts G, et al. A new framework for the documentation and interpretation of oral food challenges in population-based and clinical research. Allergy. 2017;72(3):453-61.
35. Barbarot S, Rogers NK, Abuabara K, Aubert H, Chalmers J, Flohr C, et al. Strategies used for measuring long-term control in atopic dermatitis trials: a systematic review. J Am Acad Dermatol. 2016.
36. StataCorp. CS, TX. Stata Statistical Software: Release 13. 2013. Available from: http://www.stata.com.
37. Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. 3rd ed. USA: Wiley; 2003.
38. Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value Health. 2015;18(2):161-72.
39. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. 4th ed. UK: Oxford University Press; 2015.
40. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials (Handbooks in Health Economic Evaluation). 2014.
41. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care. 2005;21(2):240-5.
42. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997;6(4):327-40.
43. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779-87.
44. Robert Boyle HW, Askie L, Lodrup-Carlsen K, Montgomery A, Chalmers J, Shimojo N, Kelleher M, Mead E. Prospectively planned meta-analysis of skin barrier studies for the prevention of eczema and associated health conditions. PROSPERO 2017:CRD42017056965. Available from: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017056965. Accessed on 17 Mar 2017.